CNCE Concert Pharmaceuticals Inc.

11.21
0  0%
Previous Close 11.21
Open 11.25
Price To Book 1.78
Market Cap 266,756,388
Shares 23,796,288
Volume 3,532
Short Ratio
Av. Daily Volume 236,147

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 8mg data released November 12, 2018 - primary endpoint met. 12mg data due 3Q 2019.
CTP-543
Alopecia areata
Phase 3 first trial data noted primary endpoint met with one of the two doses. Data due from second trial December 2019.
AVP-786
Agitation in patients with Alzheimer's disease
Phase 3 planned. Needs partner
CTP-499
Diabetic Kidney Disease
Phase 2 monotherapy trial initiated 2Q 2019.
VX-561
Cystic fibrosis who have a gating mutation
Phase 1 data presented at ASCP May 30, 2019.
CTP-692 (single dose)
Schizophrenia
Phase 2 trial to be completed 4Q 2019.
CTP-543 - open label (Once-Daily vs. Twice-Daily)
Alopecia areata
Phase 2 trial to be initiated 4Q 2019.
CTP-692
Schizophrenia
Phase 2 combo trial initiated May 2019.
VX-561 and VX-121
Cystic Fibrosis
Phase 2 second open label trial initiation announced May 16, 2019. To be completed 1H 2020.
CTP-543 - open label (12 mg twice-daily or 24 mg once-daily)
Alopecia areata

Latest News

  1. Concert Pharma's CTP-692 Positive for Schizophrenia in Phase I
  2. Concert Pharmaceuticals Reports Positive Results from Phase 1 Studies Evaluating CTP-692 in Healthy Volunteers
  3. Concert Pharmaceuticals Completes Enrollment in Open Label Trial to Evaluate Once-Daily vs. Twice-Daily Dosing of CTP-543 in Patients with Alopecia Areata
  4. Edited Transcript of CNCE earnings conference call or presentation 2-May-19 12:30pm GMT
  5. Concert Pharmaceuticals Announces Initiation of New Open Label Trial to Evaluate Once-Daily vs. Twice-Daily Dosing of CTP-543 in Patients with Alopecia Areata
  6. Concert Pharmaceuticals to Present at Upcoming Investor Conferences
  7. Why Concert Pharmaceuticals, Inc.'s (NASDAQ:CNCE) CEO Pay Matters To You
  8. Concert Pharmaceuticals, Inc. (CNCE) Q1 2019 Earnings Call Transcript
  9. Concert: 1Q Earnings Snapshot
  10. Concert Pharmaceuticals Reports First Quarter 2019 Financial Results
  11. Concert Pharmaceuticals Names Jesper Høiland to its Board of Directors
  12. Earnings Preview: Concert Pharmaceuticals (CNCE) Q1 Earnings Expected to Decline
  13. Concert Pharmaceuticals to Report First Quarter 2019 Financial Results on May 2, 2019
  14. Concert Pharma Initiates Early-Stage Schizophrenia Study
  15. Concert Pharmaceuticals to Present CTP-543 Phase 2 Interim Data in Alopecia Areata at 2019 World Congress for Hair Research Annual Meeting
  16. Concert Pharmaceuticals Initiates Phase 1 Multiple-Ascending Dose Trial of CTP-692 as an Adjunctive Treatment for Schizophrenia
  17. Concert Pharmaceuticals' stock takes a sharp dive after disappointing patent appeal board ruling
  18. Concert Pharmaceuticals Announces Decision from Patent Trial and Appeal Board in IPR Proceeding
  19. New Strong Sell Stocks for March 25th